Page 18 of 19
PA30.1-5 | Breast — Case Study
CLINICAL SCENARIO
A 48-year-old woman presents to the surgical outpatient department with a right breast lump she noticed during routine self-examination three weeks ago. She reports no nipple discharge, no skin changes, and no axillary swelling. Family history is significant: her mother was diagnosed with breast carcinoma at age 55. Clinical examination reveals a 2.5 cm firm, non-tender, ill-defined mass in the upper outer quadrant of the right breast with mild skin tethering; the ipsilateral axilla contains a single palpable lymph node.
This assignment guides you through the complete clinico-pathological work-up — from initial triple assessment through core needle biopsy interpretation, immunohistochemical (IHC) profiling, Nottingham grading, and TNM staging. You will be expected to reason through the differential diagnosis, integrate morphological and molecular findings, and discuss the prognostic and therapeutic implications of the final diagnosis. Peer reviewers will assess the quality of your pathological reasoning rather than mere recall of facts.
Instructions
Read the clinical vignette carefully before attempting any section. Your submission should read as a coherent analytical document, not a bullet-point list. Each section builds on the last; do not skip ahead.
- Begin with a structured Clinical Summary that identifies all red-flag and reassuring features from the history and examination, and state what they collectively suggest about the likely nature of the lesion.
- In the Triple Assessment section, explain each of the three components (clinical, imaging, pathological) and apply them to this patient. State what mammographic and ultrasonographic features you would expect if the lesion is malignant versus benign, and justify the need for tissue sampling.
- In the Differential Diagnosis section, systematically compare the two most important diagnoses — invasive ductal carcinoma (IDC) versus fibroadenoma — and explain which features in this patient push the probability towards malignancy. Briefly mention phyllodes tumour as a third consideration and state how it differs from fibroadenoma on histology.
- The Morphology section must describe the expected gross appearance and the light-microscopic features of the core biopsy if it confirms IDC of no special type (NST). Include: architectural patterns (tubule formation), nuclear pleomorphism, mitotic activity, and any in-situ component (DCIS). You are given the following biopsy findings to incorporate: moderately pleomorphic ductal cells arranged in irregular nests and cords with focal tubule formation (tubule formation score 2), nuclei with moderate pleomorphism (nuclear grade 2), and 8 mitoses per 10 high-power fields (mitotic score 2).
- In the Grading and Staging section, compute the Nottingham Histological Grade (Elston-Ellis modification) from the scores provided above. Then apply the UICC/AJCC TNM 8th edition to this patient, using: T2 (tumour 2.5 cm), N1 (1 palpable ipsilateral axillary node, assume confirmed on sentinel biopsy), M0 (no distant metastasis). State the overall stage group.
- The IHC and Molecular Subtypes section must interpret the following IHC panel: ER positive (Allred score 7/8), PR positive (Allred score 5/8), HER2 negative (IHC score 1+), Ki-67 index 18%. Classify the tumour into one of the four molecular surrogate subtypes (Luminal A, Luminal B HER2-negative, Luminal B HER2-positive, HER2-enriched, Triple Negative). State the prognostic significance and the systemic therapy implications (endocrine therapy, chemotherapy, targeted therapy).
- In Routes of Spread, describe how breast carcinoma spreads locally, to regional lymph nodes (axillary levels I-III, internal mammary, supraclavicular), and to distant sites (lung, liver, bone, brain) — with a brief note on which molecular subtype has the highest risk of brain metastasis.
Word guidance: 600–900 words total across all seven sections. Be concise but precise; marks are awarded for reasoning, not word count.
Length: 600-900 words
What to Submit
Clinical Summary
In 2-3 sentences, summarise the key history and examination findings. Identify at least three features that raise concern for malignancy and at least one reassuring feature. What does the overall picture suggest?
Triple Assessment
Define the triple assessment triad. For each component, state what you would expect in this patient and assign a radiological/pathological category (e.g., R4/R5, U4/U5, B4/B5). Explain why all three components must be concordant before a management decision is made.
Differential Diagnosis
Compare IDC (NST) and fibroadenoma as diagnoses for this patient's presentation. Use at least four clinical or pathological features to argue in favour of malignancy. Briefly describe how phyllodes tumour differs from fibroadenoma histologically (stroma, leaf-like architecture, cellularity).
Morphology of IDC (NST)
Using the biopsy data provided (tubule score 2, nuclear grade 2, mitotic score 2), describe the expected gross and microscopic appearances. What is the significance of an associated DCIS component? Mention any special stains or ancillary techniques you might request on the core biopsy.
Nottingham Grade and TNM Staging
Calculate the Nottingham grade step by step (sum the three component scores; state the grade and its prognostic meaning). Apply TNM 8th edition (T2 N1 M0) and state the Stage Group. What is the clinical significance of upgrading from Stage IIA to IIB in this scenario?
IHC Profile and Molecular Subtype
Interpret the ER/PR/HER2/Ki-67 results provided. Classify the molecular subtype and justify your classification. Discuss: (a) which systemic therapies are indicated, (b) which are not indicated, and (c) how the Ki-67 value influences the choice between endocrine therapy alone versus chemotherapy plus endocrine therapy.
Routes of Spread and Prognosis
Describe local, regional (lymphatic), and distant (haematogenous) routes of spread for breast carcinoma. For this patient's Luminal B profile, comment on the expected 10-year recurrence risk and the role of genomic assays (e.g., Oncotype DX) in refining that estimate.
Grading Rubric — Breast Case Study Rubric
| Criterion | Points | Full-marks descriptor |
|---|---|---|
| Clinical and Histological Integration — assesses the student's ability to link clinical red-flag features (skin tethering, ill-defined margin, axillary node) with the expected gross and microscopic pathology of IDC (NST), including tubule formation, nuclear pleomorphism, and mitotic activity. | 6 pts | All clinical red-flag features are correctly identified and directly linked to histological correlates. Gross and microscopic morphology of IDC (NST) described accurately, including DCIS component. Mention of any ancillary technique (e.g., E-cadherin, p63) adds depth. |
| Nottingham Grade Calculation and Staging — assesses accuracy of the step-by-step Nottingham grading (tubule + nuclear + mitotic scores) and correct application of UICC/AJCC TNM 8th edition staging with appropriate stage grouping. | 6 pts | Nottingham grade calculated correctly step-by-step (2+2+2=6, Grade 2) with prognostic interpretation. TNM correctly stated as T2 N1 M0, Stage IIB. Clinical significance of Stage IIB versus IIA articulated. |
| IHC Interpretation and Molecular Subtype Classification — assesses correct interpretation of the ER/PR/HER2/Ki-67 panel, accurate molecular subtype classification (Luminal B HER2-negative), and coherent explanation of systemic therapy implications (endocrine therapy, role of chemotherapy, exclusion of trastuzumab). | 8 pts | ER/PR correctly interpreted as strongly positive; HER2 correctly classified as negative (IHC 1+, no reflex ISH needed); Ki-67 18% correctly placed in the intermediate range. Molecular subtype correctly identified as Luminal B HER2-negative. Therapies discussed accurately: endocrine therapy mandated; chemotherapy role debated given Ki-67; trastuzumab correctly excluded. Genomic assay (Oncotype DX / Prosigna) mentioned as a rational next step. |
| Differential Diagnosis and Triple Assessment Reasoning — assesses systematic comparison of IDC versus fibroadenoma (and brief consideration of phyllodes tumour), use of the triple assessment framework, and quality of reasoning that drives the diagnostic conclusion. | 5 pts | Four or more specific clinical/pathological features correctly used to argue for malignancy over fibroadenoma. Triple assessment components correctly defined and applied with appropriate radiological categories (R4/U4 or R5/U5 expected). Phyllodes distinguished from fibroadenoma by stromal hypercellularity and leaf-like architecture. |
| Routes of Spread and Prognostic Synthesis — assesses accurate description of local, lymphatic, and haematogenous spread, correct identification of common metastatic sites for breast carcinoma, and a coherent prognostic synthesis that integrates grade, stage, and molecular subtype for this patient. | 5 pts | Local spread (skin, pectoral fascia), lymphatic routes (axillary levels I-III, internal mammary, supraclavicular), and haematogenous spread (bone most common, then lung, liver, brain) all accurately described. Correctly notes that Triple Negative subtype (not this patient's) carries the highest brain metastasis risk. Prognostic synthesis integrates Grade 2, Stage IIB, and Luminal B subtype coherently, with mention of 10-year recurrence risk. |
PEER REVIEW
You will be assigned one peer submission to review. Your role is to act as a critical but constructive reviewer, not an editor. Follow these steps:
- Read the full submission once before scoring anything.
- For each rubric criterion, assign a score using the rating descriptions provided. Do not award partial points between levels — select the level that best matches the work.
- For the IHC criterion (8 points), pay particular attention to whether the molecular subtype classification is correct and whether the therapy discussion excludes trastuzumab for this HER2-negative patient. This is a high-stakes reasoning step.
- For the Nottingham Grade criterion, check the arithmetic: tubule 2 + nuclear 2 + mitotic 2 = 6, which places the tumour in Grade 2. If the peer states Grade 1 or Grade 3 without justification, deduct accordingly.
- Write at least two specific, evidence-based comments per criterion: one identifying a strength and one identifying a gap or error. Generic comments such as 'good job' or 'needs more detail' without specifics will not be accepted.
- Conclude your review with a 3-5 sentence overall comment that summarises the submission's main analytical strength and the single most important area for improvement.
- You are not expected to provide the model answer. You are expected to reason about whether the peer has reasoned correctly.